Inicio > Endocrinología y Nutrición > Diabetes mellitus y cáncer. Estrategia en el paciente oncológico > Página 5

Diabetes mellitus y cáncer. Estrategia en el paciente oncológico

303:446–447PubMedCrossRef

49- Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause- specific death. N Engl J Med 364:829–841PubMedCrossRef

50- Pollak M (2009) Do cancer cells care if their host is hungry? Cell Metab 9:401–403PubMedCrossRef

51- Johnson JA, Pollak M (2010) Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia 53:2086–2088PubMedCrossRef

52- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body- mass index and incidence of cancer: a systematic review and meta- analysis of prospective observational studies. Lancet 371:569–578PubMedCrossRef

53- World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington DC

54- Suissa S (2008) Immortal time bias in pharmaco- epidemiology. Am J Epidemiol 167:492–499PubMedCrossRef

55- Rewers M (2008) Why do people with diabetes die too soon? Diabetes Care 31:830–831PubMedCrossRef

56- Evans JMM, Donnelly LA, Emslie- Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305PubMedCrossRef

57- Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose- lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777PubMedCrossRef

58- Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625PubMedCrossRef

59- Yang YX, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044–1050PubMedCrossRef

60- Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer- related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258PubMedCrossRef

61- Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744PubMedCrossRef

62- Mannucci E, Monami M, Balzi D et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin- treated type 2 diabetic patients. Diabetes Care 33:1997–2003PubMedCrossRef

63- Lewis JD, Ferrara A, Peng T et al (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916–922PubMedCrossRef

64- Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M (2010) Metformin blocks the stimulative effect of a high- energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17:351–360PubMedCrossRef

65- olhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755–1765, Erratum 52:2469PubMedCrossRef

66- Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon- like peptide- 1- based therapies. Gastroenterology 141:150–156PubMedCrossRef

67- Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499–2506PubMedCrossRef

68- Home PD, Kahn SE, Jones NP, Noronha D, Beck- Nielsen H, Viberti G, ADOPT Study Group; RECORD Study Steering Committee (2010) Experience of malignancies with oral glucose- lowering drugs in the randomized controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes) clinical trials. Diabetologia 53:1838–1845PubMedCrossRef

69- Johnson JA, Yasui Y (2010) Glucose- lowering therapies and cancer risk: the trials and tribulations of trials and observations. Diabetologia 53:1823–1826PubMedCrossRe